These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24956144)

  • 1. Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
    Olszewski AJ; Shafqat H; Ali S
    Leuk Lymphoma; 2015 Apr; 56(4):942-50. PubMed ID: 24956144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
    Olszewski AJ; Butera JN; Reagan JL; Castillo JJ
    Am J Hematol; 2020 Apr; 95(4):354-361. PubMed ID: 31849108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
    Vidal L; Gafter-Gvili A; Gurion R; Raanani P; Dreyling M; Shpilberg O
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009045. PubMed ID: 22972131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
    Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
    Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
    Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
    Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
    Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
    BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
    Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
    Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
    Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
    Odejide OO; Cronin AM; Davidoff AJ; LaCasce AS; Abel GA
    Leuk Lymphoma; 2015 Mar; 56(3):716-24. PubMed ID: 24913508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.
    Levy V; Porcher R; Delabarre F; Leporrier M; Cazin B; Chevret S;
    J Clin Epidemiol; 2001 Jul; 54(7):747-54. PubMed ID: 11438417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.
    Çağlayan Ç; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):300-309.e5. PubMed ID: 30686772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
    Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
    Levitt MJ; Gharibo M; Strair R; Schaar D; Rubin A; Bertino JR
    J Chemother; 2009 Aug; 21(4):434-8. PubMed ID: 19622463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.
    Satram-Hoang S; Reyes C; Hoang KQ; Momin F; Skettino S
    Ann Hematol; 2014 Aug; 93(8):1335-44. PubMed ID: 24638841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
    De Angelis F; Tosti ME; Capria S; Russo E; D'Elia GM; Annechini G; Stefanizzi C; Foà R; Pulsoni A
    Leuk Res; 2015 Dec; 39(12):1382-8. PubMed ID: 26547259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
    Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
    Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.